Navigation Links
Perrigo Company Confirms FDA Tentative Approval for Clobetasol Propionate Emulsion Foam
Date:10/6/2011

ALLEGAN, Mich., Oct. 6, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) announced that it received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Emulsion Foam, 0.05%. Perrigo believes it is first-to-file on this product.

On July 12, 2010, Stiefel Research Australia Pty. Ltd. filed a patent infringement suit in the United States District Court for the District of Delaware to prevent Perrigo from commercializing this product.  This action, which is still pending, formally initiated the process under the Hatch-Waxman Act.

The product is the AB-rated equivalent to Stiefel Laboratories' Olux® -E Foam, 0.05%, a topical corticosteroid indicated for the treatment of moderate to severe dermatosis of the scalp. Sales for the brand were approximately $40 million, according to Wolters Kluwer data for the twelve months ending September 2011.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This tentative approval reflects our strategy to be first to market with the important products that make quality healthcare more affordable for our customers and drive value for our shareholders, it is also another example of the excellent partnership we have with Cobrek for developing foam products which is a key product category for our Rx business."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo to Host Analyst Day on October 5, 2011 at the TASE, Tel Aviv Stock Exchange in Tel Aviv, Israel
2. Perrigo to Host Analyst Day on September 27, 2011 at the NASDAQ MarketSite in Times Square
3. Perrigo Announces FDA Final Approval for Ketoconazole Foam, 2%
4. Perrigo Company Will Release Fourth Quarter Fiscal 2011 Results on August 16, 2011
5. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
6. Perrigo Closes Acquisition of Paddock Labs
7. Perrigo Receives FDA Approval to Market Coated Cinnamon Nicotine Gum
8. Perrigo Provides Update on Acquisition of Paddock Labs
9. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
10. Perrigo Company to Present at the Goldman Sachs 32nd Annual Global Health Care Conference
11. Perrigos Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... According to a new ... by Method (Biochemical (Calcium Phosphate, Lipofection, Dendrimers), Physical ... User - Global Forecast to 2021", published by ... 2016 to 2021. This market is expected to ... 715.4 Million in 2016, at a CAGR of ...
(Date:1/13/2017)... January 13, 2017 The 2016 election ... with several states voting in favor of legalizing cannabis for ... Cannabis market in the U.S. In addition, the state of ... in annual cannabis products sales. The ArcView Group has published ... the legal cannabis sales in the U.S. last year reached $6.7 ...
(Date:1/13/2017)... YORK , Jan. 12, 2017  Rosen Law ... filing of a class action lawsuit on behalf of ... ALXN ) from February 10, 2014 through November 9, ... recover damages for Alexion investors under the federal securities ... go to http://rosenlegal.com/cases-991.html or call Phillip ...
Breaking Medicine Technology:
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... today announced the addition of Victor Giamos, MD to their medical staff, ... and Managing Partner at North Shore Eye Care, a division of SightMD. Dr. ...
(Date:1/16/2017)... ... January 16, 2017 , ... Atlanta-based incentive company ... innovator in the wheelchair accessibility industry, BraunAbility . Incentive Solutions will provide ... wheelchair accessible vehicles. With this new incentive plan, BraunAbility plans to continue their ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic surgeon Dr. ... the official journal of The American Society for Aesthetic Plastic Surgery, in which ... is designed to correct drooping, retracted lower eyelids, which usually result from genetics, ...
(Date:1/16/2017)... ... January 16, 2017 , ... San Francisco dentist, Dr. ... latest in 3-D scanning device which is capable of taking digital impressions of teeth ... dentistry, such as CAD CAM restorations , in terms of speed, efficiency and ...
(Date:1/15/2017)... ... ... In this role, Courtney will be responsible for developing new business initiatives ... mark. This certification program was created by ASL and the nonprofit Asthma and Allergy ... for the 60+ million people living in the U.S. with asthma and allergies. Courtney ...
Breaking Medicine News(10 mins):